Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs
Details
Location:
EU 27
Funding agency:
Contracting Authority Type:
Development Institution
Status:
Closed
Budget:
Euro 60,000,000
Award ceiling:
N/A
Award floor:
N/A
Sector:
Health, Science & Innovation
Eligible applicants:
Unrestricted / Unspecified, Individuals
Eligible nationalities:
Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Argentina, Armenia, Aruba, Austria, Azerbaijan, Azores, Bangladesh, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, British Virgin Islands, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canary Islands, Cape Verde, Caribbean Netherlands, Cayman Islands, Central African Republic, Chad, Chile, Colombia, Comoros, Congo, Costa Rica, Cote d'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Dem. Rep. Congo, Denmark, Djibouti, Dominica, Commonwealth of, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Estonia, Eswatini (Swaziland), Ethiopia, Falkland Islands, Faroe Islands, Fiji, Finland, France, French Polynesia, French Southern Territory, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Micronesia, Moldova, Mongolia, Montenegro, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Caledonia, Nicaragua, Niger, Nigeria, North Korea, North Macedonia, Norway, Pakistan, Palau, Palestine / West Bank & Gaza, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Poland, Portugal, Romania, Rwanda, Saint Helena, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Serbia, Seychelles, Sierra Leone, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, St. Pierre and Miquelon, Sudan, Suriname, Sweden, Switzerland, Syria, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Tunisia, Turkey, Turkmenistan, Turks and Caicos, Tuvalu, Uganda, Ukraine, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Wallis and Futuna, Yemen, Zambia, Zimbabwe
Date posted:
29 Jun, 2021
Description
Horizon Europe is the EU’s key Research and Innovation program with a budget of 95.5 billion euros whose goals include tackling climate change, supporting the achievement of the UN’s Sustainable Development Goals, and enhancing the EU’s competitiveness and development.
Horizon Europe calls for pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs.
All proposals under this topic should have the goal of bringing results that are focused on and contribute to the outcomes listed below:
- Scientific and clinical communities provide effective utilization of the pre-clinical validation of new immunotherapies aimed at high burden diseases or disorders with unmet medical needs.
- Scientific and clinical communities are granted access to new knowledge to achieve an improved understanding of the type of action of the next generation of immunotherapies and/or combinatorial treatments which facilitates further improvement and optimization of treatments.
- Health care experts are granted access to and make use of new evidence-based safety and efficacy guidelines for immunotherapies.
Projects can make use of the nanobiotechnology platform of the European Commission’s Joint Research Centre.
The program is open to any legal entity, irrespective of its place of establishment. This includes legal entities coming from non-associated third countries or international organisations. The applicant must meet all the conditions found in the Horizon Europe Regulations.
Opening date: October 6, 2021.
First stage deadline: February 1, 2022, 17:00:00 Brussels time.
Second stage deadline: September 6, 2022, 17:00:00 Brussels time.